Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction (PSB-AF)
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Zhaohui Qiu
- 電話番号:+862152039999
- メール:qzh3503@shtrhospital.com
研究場所
-
-
Anhui
-
Anqing、Anhui、中国
- まだ募集していません
- China Medical University affiliated AnQing Municipal Hospital
-
コンタクト:
- Liangchuan Chen
- 電話番号:+86 13956556381
- メール:aqslyy@163.com
-
Tongling、Anhui、中国
- まだ募集していません
- Tongling People's Hospital
-
コンタクト:
- Ying Zhang
- 電話番号:+86 18005669636
- メール:tlph@mail.wh.ah.cn
-
-
Guizhou
-
Zunyi、Guizhou、中国
- まだ募集していません
- Affiliated Hospital of Zunyi Medical College
-
コンタクト:
- Xianping Long
- 電話番号:+86 13885294999
- メール:longxianping1201@163.com
-
-
Hubei
-
Wuhan、Hubei、中国
- まだ募集していません
- Wuhan Asia General Hospital
-
コンタクト:
- Hongwei Han
- 電話番号:+86 15327298622
- メール:wuhanagh@163.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200336
- 募集
- Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
-
コンタクト:
- Zhaohui Qiu
- 電話番号:+862152039999
- メール:qzh3503@shtrhospital.com
-
Shanghai、Shanghai Municipality、中国
- まだ募集していません
- Fudan University affiliated Huadong Hospital
-
コンタクト:
- Zhengqi Kong
- 電話番号:+86 13816620347
- メール:huadongtexu@163.com
-
Shanghai、Shanghai Municipality、中国
- まだ募集していません
- Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
-
コンタクト:
- Zongqi Zhang
- 電話番号:+86 18049827281
- メール:zqzhang_scdc@126.com
-
Shanghai、Shanghai Municipality、中国
- まだ募集していません
- Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
-
コンタクト:
- Yisheng Pan
- 電話番号:+86 13817273883
- メール:shlygjyl@163.com
-
Shanghai、Shanghai Municipality、中国
- まだ募集していません
- Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
-
コンタクト:
- Zongjun Liu
- 電話番号:+86 19821577439
- メール:lzj72@126.com
-
Shanghai、Shanghai Municipality、中国
- まだ募集していません
- Tongji University School of Medicine affiliated Tongji University
-
コンタクト:
- Bing Sun
- 電話番号:+86 13918324334
- メール:woowoocncn@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years
- Indication for permanent pacemaker implantation, including:
- Sinus node dysfunction, defined as at least one of the following:
- Symptomatic sinus bradycardia
- Tachy-brady syndrome
- Chronotropic incompetence
- Sinus pause / arrest
- Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
- Expected survival >1 year
- Panned implantation of a device capable of detecting atrial high-rate episodes
- Willing and able to provide informed consent
Exclusion Criteria:
- Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
- Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
- Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
- Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
- Acute myocardial infarction within 3 months before enrollment
- Persistent left superior vena cava or dextrocardia
- Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception
- Participation in another clinical trial that may interfere
- Any condition that, in the opinion of the investigator, makes participation unsuitable
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:PSB pacing
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
|
アクティブコンパレータ:RAA pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of atrial fibrillation
時間枠:From implantation to regular follow-ups up to 24 months
|
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups |
From implantation to regular follow-ups up to 24 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Atrial high-rate episodes
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
AF burden
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
eGFR
時間枠:At baseline, before discharge, and 6 - month follow-up
|
At baseline, before discharge, and 6 - month follow-up
|
|
|
All-cause mortality
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Cardiovascular death
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Intrinsic P-wave duration
時間枠:At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
Measured from the onset of the P wave to the end |
At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
|
Paced P-wave duration
時間枠:From implantation to regular follow-ups up to 24 months
|
Measured from the pacing stimulus to P wave end duration |
From implantation to regular follow-ups up to 24 months
|
|
Left ventricular ejection fraction (LVEF)
時間枠:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left atrial diameter (LAD)
時間枠:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Right atrial diameter (RAD)
時間枠:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-systolic diameter (LVESD)
時間枠:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-diastolic diameter (LVEDD)
時間枠:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
E/e'
時間枠:At baseline, 6-, 12- , 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12- , 24-month follow-ups
|
|
Mitral regurgitation severity
時間枠:At baseline, 6-, 12- , 24-month follow ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12- , 24-month follow ups
|
|
Tricuspid regurgitation severity
時間枠:At baseline, 6-, 12-, 24- month follow-ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12-, 24- month follow-ups
|
|
NT-pro BNP
時間枠:At baseline, before discharge, and 6-month follow-up
|
Standard transthoracic echocardiographic parameter |
At baseline, before discharge, and 6-month follow-up
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Atrial pacing capture threshold
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial sensing amplitude
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial pacing output
時間枠:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Procedural complications
時間枠:Perioperative
|
Safety Outcome |
Perioperative
|
|
Postoperative adverse events
時間枠:From implantation to regular follow-ups up to 24 months
|
Safety Outcome, including lead-related complications, thromboembolic events, etc. |
From implantation to regular follow-ups up to 24 months
|
|
Paced P-wave morphology
時間枠:From implantation to regular follow-ups up to 24 months
|
positive, negative, notched, and biphasic |
From implantation to regular follow-ups up to 24 months
|
|
Intrinsic P-wave morphology
時間枠:At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
positive, negative, notched, and biphasic |
At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- PSB-AF
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。